This trial is conducted in Asia. The aim of this trial is to investigate the pharmacokinetic (the exposure of the trial drug in the body) properties of insulin degludec/insulin aspart in healthy Chinese subjects.

Inclusion Criteria:

• Male or female Chinese subject aged 18-45 years (both inclusive)
• Considered generally healthy upon completion of medical history, physical examination, vital signs and electrocardiogram (ECG), as judged by the investigator
• Body mass index 19.0-24.0 kg/m^2 (both inclusive)

Exclusion Criteria:

• A history of any illness that, in the opinion of the investigator, might confound the results of the trial or pose risk in administering the trial product to the subject
• Subject who has donated any blood or plasma in the past month or more than 400 mL within 3 months prior to screening
• Smoking more than 5 cigarettes (including nicotine substitute products), or the equivalent, per